Dr Venkata Pradeep babu Koyyala bhawna sirohi bhawna sirohi, I worked with Venkata on a project and he was amazing! He coordinated 41 colleagues from India in the translation of patient information sheets for Biliary Cancers into 13 Indian languages. thelancet.com/journals/lanon…

🏆 AIOM Fondazione Aiom

Paper 2: Phase 3 trial of KRAS G12C inhibitor #sotorasib + #panitumumab demonstrated ⬆️ PFS in patients with chemo-refractory metastatic colorectal cancer. NEJM Dr. Marwan G. Fakih Filippo Pietrantonio nejm.org/doi/full/10.10…

Early onset GI cancers will be highlighted at ASCO #GI24 EO-EGC is rising along with CRC. Our results in JNCI show EO-EGC is: ⬆️gastric ⬆️diffuse type 🟰 stage/survival Much still unknown Fantastic collaboration Andrea Cercek Yelena Y. Janjigian MD Steve Maron Memorial Sloan Kettering Cancer Center

Happy to share latest international collaboration led by awesome Arnav Mehta Minae An and others. Jeeyun Lee MD Cancer Discovery SU2Cscience Early immune remodeling steers clinical response to frontline chemoimmunotherapy in advanced gastric. aacrjournals.org/cancerdiscover…

AI-assisted transcriptomic signatures: a key step in personalizing pancreatic cancer treatment. : jle.com/en/revues/ito/…

Very important data in light of the ongoing PURITY study (NCT06037980) by Monica Niger and GONO Foundation

What are the treatment patterns and outcomes for patients with BRAF-mutant mCRC after progression to encorafenib/cetiximab? In this article, Dr. Germani et al. report data from a large 🇮🇹 cohort, suggesting improved outcomes when TT is administered early. esmoopen.com/article/S2059-…

Big year for gastroesophageal at #ASCO24 ASCO ESOPEC plenary EA2174, ARMANI, and RENAISSANCE in the oral sessions. Karyn Goodman, MD, MS Nataliya Uboha Filippo Pietrantonio ECOG-ACRIN Cancer Research Group Lorenzo Ferri MD PhD @FlorianLordick Yelena Y. Janjigian MD Kohei shitara Sara Lonardi Lizzy Smyth Raghav Sundar

ESOPEC trial It’s been a long 15 year journey, but so nice to see Docetaxel triplets come on top for the benefit of our patients! CROSS just doesn’t work for GEA-EAC- radiation compensates for poor surgical control (trans-hiatal) and CM577 compensates for poor systemic control

Updated and OS results of Atezotribe by GONO Foundation 🇮🇹 Confirmed role of IS IC as biomarker of ICI sensitivity in pMMR mCRC. Carlotta_Antoniotti Filippo Pietrantonio Sara Lonardi Lisa Salvatore Daniele Rossini ascopubs.org/doi/10.1200/JC…

Best colleagues and friends ever! Ready for Atezo2!

Promising combination for mCRC patients not fit for classical 1st line doublet chemo, personally I love this trial by GONO Foundation !

Un successo il Congresso Nazionale di AIOM Giovani 2024. Un grande lavoro del Working Group giovani. #AIOM #CongressoNazionaleAIOMgiovani

How long should we treat our pts with MSI-H #mCRC with immune checkpoint inhibitors to preserve efficacy while optimizing toxicities and costs? In our academic international study 🇮🇹🇫🇷🇺🇸 ETD within 1 year is not detrimental vs a longer duration. RCT are now warranted🔜 #ESMO24

☢️Neoadjuvant CRT vs. ChT for initially unresectable locally advanced "Colon" cancer eClinicalMedicine – The Lancet Discovery Science ➡️45 patients ✅R0 resection: 80% vs. 20%, P < 0.001 ✅3-year PFS: 76% vs. 45% , P = 0.049 ✅3-year OS: 87.6% vs. 75% , P = 0.037 ✅No differences in severe AEs ❗️Study was

The one & only one Raffaella Casolino 🇺🇳 delivering the Keynote lecture at AIOM meeting in #Venice right now ! ✨ An illuminating perspective on #Cancer control amidst Humanitarian Challenges ✨ World Health Organization (WHO) #UHC Fondazione Aiom #LeGiornateDellEtica #SanServolo

KRASG12D-Mutated Metastatic #ColorectalCancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration: brnw.ch/21wOBSV Chiara Cremolini, GONO Foundation #CRCSM

Ramucirumab/paclitaxel as switch maintenance vs continuation of FOLFOX HER2-negative GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎ARMANI phs 3 👉mPFS 6·6 vs 3·5 mo 👉mOS 12·6 vs 10·4 mo 🧐switch maintenance could be an option for pts who are not eligible for

Our review and evidence-based algorithm on late-line treatment options for metastatic colorectal cancer patients 👉 rdcu.be/d0AHE Chiara Cremolini Vittorio Studiale carlottanto NatureRevClinOncol